Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
Authors:
Open Access
- 23 January 2007
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 96 (2) , 255-261
Abstract
Bisphosphonates (BPs) are widely used to treat bone diseases and also appear to possess direct antitumour activity. We have previously reported that third-generation BPs such as zoledronic acid (ZOL) and minodronic acid (YM529) synergistically augment the effects of anticancer agents in various cancer cells. Recently, we have also reported the antitumour effects of YM529 on murine osteosarcoma cells. As YM529 has not been clinically available, we herein focused on the anti-osteosarcoma effects of ZOL which is clinically available. In addition to ZOL alone, we evaluated the concurrent or sequential combined effects of ZOL with other anticancer agents against murine osteosarcoma cell lines. ZOL showed almost same anti-osteosarcoma activity compared with YM529 and more sensitive growth inhibitory effects against osteosarcoma cells than normal cells. Moreover, ZOL acted synergistically in vitro when administered concurrently with paclitaxel (PAC) or gemcitabine (GEM), not only in wild-type osteosarcoma cells but also in P-glycoprotein (P-gp)-overexpressing osteosarcoma cells, which were much less sensitive against each anticancer agent. Furthermore, 24 h of ZOL pretreatment significantly augmented the sensitivity of doxorubicin (DOX), PAC or GEM against osteosarcoma cells. These findings suggest that combined administration of ZOL with other anticancer agents may improve the osteosarcoma treatment.Keywords
This publication has 38 references indexed in Scilit:
- The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosisCancer Letters, 2006
- Zoledronic Acid (Zometa®) Enhances the Cytotoxic Effect of Gemcitabine and Fluvastatin: In vitro Isobologram Studies with Conventional and Nonconventional Cytotoxic AgentsOncology, 2006
- Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancerBritish Journal of Cancer, 2006
- Anticancer effects of zoledronic acid against human osteosarcoma cellsJournal of Orthopaedic Research, 2006
- Mechanisms and strategies to overcome multiple drug resistance in cancerFEBS Letters, 2006
- Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell linesLung Cancer, 2005
- The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylateBlood, 2003
- Phase II trial of gemcitabine in advanced sarcomasCancer, 2002
- Increase in topoisomerase‐II‐mediated dna breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexateInternational Journal of Cancer, 1990
- Radiation-induced osteogenic sarcoma of C3H mouse: Effects of Corynebacterium parvum and WBI on its natural history and response to irradiation1979